Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Bevacizumab for HHT-Related Epistaxis
NCT02389959Phase 4Completed
- Sponsor
- Stanford University
- Start
- Aug 2014
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) (2 arms), sponsored by Stanford University. Primary endpoint: Epistaxis Severity Score at 6 months. Started Aug 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT02389959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389959.